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Abstract
Background: Brain atrophy and cognitive dysfunction are neurodegenerative features of Multiple Sclerosis (MS). We used a
candidate gene approach to address whether genetic variants implicated in susceptibility to late onset Alzheimer’s Disease
(AD) influence brain volume and cognition in MS patients.
Methods/Principal Findings: MS subjects were genotyped for five single nucleotide polymorphisms (SNPs) associated with
susceptibility to AD: PICALM, CR1, CLU, PCK1, and ZNF224. We assessed brain volume using Brain Parenchymal Fraction (BPF)
measurements obtained from Magnetic Resonance Imaging (MRI) data and cognitive function using the Symbol Digit
Modalities Test (SDMT). Genotypes were correlated with cross-sectional BPF and SDMT scores using linear regression after
adjusting for sex, age at symptom onset, and disease duration. 722 MS patients with a mean (6SD) age at enrollment of 41
(610) years were followed for 44 (628) months. The AD risk-associated allele of a non-synonymous SNP in the PCK1 locus
(rs8192708
G) is associated with a smaller average brain volume (P=0.0047) at the baseline MRI, but it does not impact our
baseline estimate of cognition. PCK1 is additionally associated with higher baseline T2-hyperintense lesion volume
(P=0.0088). Finally, we provide technical validation of our observation in a subset of 641 subjects that have more than one
MRI study, demonstrating the same association between PCK1 and smaller average brain volume (P=0.0089) at the last MRI
visit.
Conclusion/Significance: Our study provides suggestive evidence for greater brain atrophy in MS patients bearing the PCK1
allele associated with AD-susceptibility, yielding new insights into potentially shared neurodegenerative process between
MS and late onset AD.
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Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating disease
of the central nervous system (CNS) that leads to brain atrophy and
cognitive impairment [1,2]. Cognitive dysfunction occurs in all
stages of the disease, including the clinically isolated demyelinating
syndrome (CIS) stage [3]. Impaired cognitive domains in MS
include attention, processing speed, memory, executive function,
and visual spatial perception [2,4]. In Relapsing Remitting MS
(RRMS), cortical demyelinating lesion burden and brain atrophy
are both associated with cognitive dysfunction [5]. Similar to
Alzheimer’s disease (AD), brain atrophy and cognitive decline in
MS occur in a progressive and non-remitting pattern but at a slower
rate than AD for most MS patients [2,4,6].
Evidence supporting the existence of genetic factors that may
influence brain atrophy and cognitive dysfunction in MS are
emerging. For example, there is evidence that HLA DRB1*1501
and HLA B*4402 affect both brain atrophy and cognitive decline
[7,8,9]. In this study, we explored the hypothesis that elements of the
neurodegenerative process may be shared between MS and late onset
AD, the most common neurodegenerative disease with manifestation
of cognitive dysfunction typically after 65 years of age. The best-
studied candidate gene for neurodegeneration in MS is APOE
(apoliporotein E) with its e4 allele conferring increased risk for AD,
but the role of the APOE locus in MS remains unclear [10,11,12].
To address our hypothesis, we took a candidate gene approach
and explored whether susceptibility alleles for AD other than
APOE impact brain volume and cognition in a prospective cohort
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significant evidence of association with AD susceptibility as well as
independent replication: PICALM (phosphatidylinositol-binding
clathrin assembly protein) [13], CR1 (complement component 3b/
4b receptor 1) [14], and CLU (clusterin or apolipoprotein J)
[13,14]. We additionally selected PCK1 (phosphoenolpyruvate
carboxykinase 1) [15] and ZNF224 (zinc finger protein 224) [16],
two loci with suggestive evidence of association from AD genome-
wide scans, and for which our group recently demonstrated
association with age-related cognitive decline [17]. We present
evidence that at least one of these loci may have a role in
neurodegenerative events that occur in MS.
Methods
Participants
Using documents and protocols approved by the Institutional
Review Board of Partners Healthcare, each subject gave written
informed consent for their DNA, imaging data and clinical
information for analysis. Subjects were enrolled between 2000 and
2010 at the Partners Multiple Sclerosis Center, and included
participants in the Comprehensive Longitudinal Investigation of
Multiple Sclerosis at the Brigham and Women’s Hospital
(CLIMB), an ongoing prospective cohort study based in the New
England area. For this study, we only included subjects of self-
reported non-Hispanic Caucasians between 18 and 65 years of age
during the follow-up period who met the revised McDonald
diagnostic criteria [18,19] or had a diagnosis of CIS. Primary
Progressive MS (n=1) was excluded because of its possibly
different pathophysiology from the other subsets of MS subjects
and the fact that only one subject in this category had both
genotype and imaging data. We limited analysis to three MS
subcategories: relapsing-remitting (RRMS), secondary progressive
(SPMS), progressive relapsing (PRMS).
Genotyping Data
We considered five AD-associated SNPs in our cohort: PICALM
(rs3851179), CR1 (rs6656401), CLU (rs11136000), PCK1 (rs8192708),
and ZNF224 (rs3746319). Genotyping were performed on the
Affymetrix Genome-wide Human SNP Array 6.0 (Genechip 6.0) at
theBroadInstitute’sCenterforGenotypingandprocessedforquality
control using the PLINK software suite as previously described
[20,21]. In short, we applied the standard quality control pipeline for
subjects (genotype success rate .95%, genotype-derived gender
concordant with reported gender, excess inter/intra-heterozygosity)
and for SNPs (Hardy-Weinberg Equilibrium p.1610
26;M i n o r
Allele Frequency .0.01, genotype call rate .0.95).
Assessment of HLA B*44 Status
Because the best surrogate marker (rs2743951) for HLA B*4402
was not genotyped in the array, a surrogate SNP (rs2523393) was
selected based on its strong linkage disequilibrium (r
2=0.92) with
rs2743951 in the HapMAP CEU samples [21]. We classified HLA
B*4402 based on the presence of the protective allele at this SNP
(rs2523393
GG or GA, 67% of the cohort) or the absence of the
protective allele (rs2523393
AA, 33% of the cohort).
Clinical Data
Clinical data were obtained from the Partners MS Center
Oracle relational database. At each clinic visit, the Extended
Disability Status Scale (EDSS) score was measured on each
patient. Disease duration was defined as the time interval from the
self-reported symptom onset to recorded clinic visit.
Radiographic Data
The neuroimaging approach in this cohort have been described in
detail elsewhere [22]. In short, routine clinical MRI scans were
obtained on 1.5 Tesla system (Signa, GE Medical Systems,
Milwaukee, WI) using a standard bird-cage quadrature coil [23].
Images included T1-weighted proton density and T2-weighted axial
images of 3-mm thick sections. Each brain was segmented using an
automated template-driven pipeline, and brain parenchymal fraction
(BPF) and T2-hyperintense lesion volume (T2LV) were calculated for
eachMRIscan [24,25].Adetailed description ofradiological analysis
is described in the supplemental methods (Appendix S1).
Cognitive Data
The Symbol Digit Modalities Test (SDMT) measures working
memory and information processing speed using a complex visual
scanning and tracking task. SDMT has been validated in MS and
performance on SDMT is independent of physical disability
[26,27]. Subjects were given 90 seconds to substitute numbers for
symbols as part of a pre-defined code with the final score being the
total number of correct items.
Statistical Methods
Demographic characteristics of the cohort are described using
means and standard deviations for continuous variables and
frequency and proportions for categorical variables. Linear
regression was used to assess the relationship between each SNP
and the primary outcomes (BPF and SDMT) at baseline (defined
as study entry). For primary analyses, we implemented an additive
model that examines the effect of each additional risk allele on
outcome. We used linear mixed effects models to compare the rate
of change over time in primary outcomes (BPF and SDMT) for the
genotypes. If a significant association was found at P,0.005 (given
the five SNPs and two primary outcomes), we examined the
relationship further using (1) a dominant model comparing the
homozygote for the non-risk allele to the combined heterozygote
and homozygote for risk allele, and (2) a recessive model
comparing the combined homozygote and heterozygote for the
non-risk allele to the homozygote for the risk allele. For technical
validation of significant association, we applied the same additive
model and linear regression to assess the effect of genotype on
primary outcomes at the last visit. All models were adjusted for
sex, age of symptom onset, and disease duration.
In secondary analysis, we assessed whether HLA B*4402
interacts with the correlation between AD-associated SNP and
MS outcome. If an interaction was found, subjects were stratified
into two subgroups: HLA B*4402 positive (rs2523393
GG or GA)o r
negative (rs2523393
AA). If no interaction was found, we assessed
HLA B*4402 status as a possible confounder covariate.
In addition to assessing each individual SNP, we calculated for
each subject a cumulative genetic risk score (GRS), defined as the
number of AD-associated risk alleles from our list of five candidate
genes. The same linear regression model was used to examine the
relationship between GRS and the outcomes.
Finally, if there is a significant association between a candidate
SNP and BPF, we performed causal pathway analyses using
Cooper’s Local Causal Discovery algorithm [28] to determine
whether the relationships between candidate SNP and BPF is
mediated by T2LV. All tests were performed using SAS (version
9.2; SAS Institute, Cary, NC).
Results
The characteristics of the 722 MS subjects of self-reported
European ancestry with genotype and at least one MRI scan are
PCK1 and Brain Volume in MS
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e14169summarized in Table S1. Of those, 318 subjects additionally have
cognitive data. Serial MRI measures are availablein 641 subjects. For
the primary analysis, we used an additive model to assess whether the
following late onset AD-associated variants influence brain atrophy
and cognitive dysfunction in MS patients: PICALM (rs3851179), CR1
(rs6656401), CLU (rs11136000), PCK1 (rs8192708), and ZNF224
(rs3746319). Genotype distributions for each SNP within our cohort
are described in the supplemental section (Table S2).
Genotype Correlation with Brain Volume and Cognition
Of the tested AD-associated variants, the CR1, CLU, PICALM and
ZNF224 loci do not significantly impact baseline brain volume or
cognition (Table 1). However, we found a significant association
between rs8192708 in the PCK1 locus and baseline brain volume
(Table 1). Specifically, we examined whole brain volume using
brain parenchymal fraction (BPF), and found that the average
baseline BPF is smaller for each additional risk allele of PCK1
(rs8192708
G,b e t a=20.0087, P=0.0047) (Figure S1). This result
meets a Bonferroni-corrected threshold of significance (P,0.01)
givenfiveSNPsweretestedwiththeprimaryoutcome(BPF)usingan
additive model in the primary analysis. The effect of this risk allele
may be dominant as P-value is 0.0041 in this model for baseline BPF
(Figure 1). No significant association was observed when applying a
recessive model (P=0.37).ThePCK1 risk allele (rs8192708
G)d o e s
not impact our baseline cognitive measure, SDMT, which is
available in a subset of 318 subjects (beta=21.23, P=0.36).
Interestingly, the PCK1 risk allele is correlated with greater average
baseline T2-hyperintense lesion volume (beta=0.83, P=0.0088).
Finally, wedid not observe a correlation between thePCK1riskallele
and the baseline EDSS (beta=0.20, P=0.13).
Since an independent MS cohort of equivalent size with MRI
data was not available for replication, we assessed the correlation
between PCK1 and BPF within our subjects at a different time point.
Thus, we examined the subgroup of 641 subjects with two or more
MRI scans (90% of the cohort) and found the same significant
correlation between the rs8192708
G risk allele and smaller average
BPF at the last MRI time point (beta=20.009, P=0.0089). This
provides a technical validation of our observation since the analysis
uses an independent measure of BPF in our subjects.
HLA B*44 and PCK1
In a secondary analysis, we investigated whether a surrogate
marker for HLA B*4402 modifies the effects of the PCK1 variant
(rs8192708) on baseline brain volume given that we have
previously reported an association between HLA B*4402 and
higher BPF in MS subjects [7]. In our subjects, we found an
interaction between HLA B*4402 and rs8192708 for BPF
(P=0.0095). In stratified analyses, the association between the
rs8192708
G allele and smaller baseline BPF is driven by the HLA
B*4402 positive subgroup (n=463, beta=20.014, P=9.2610
25).
The HLA B*4402 negative subgroup demonstrates no significant
association with the PCK1 locus (n=259, P=0.53).
Genetic Risk Score Correlation with Brain Volume and
Cognition
To assess whether the five tested loci have a modest effect on
our outcome measures, we calculated an aggregate, non-weighted
Figure 1. Effect of PCK1 (rs8192708
G) on the baseline brain
volume using a dominant model. The dominant model provides
the best fit for the effect of PCK1 (rs8192708
G) on the baseline brain
volume as measured by brain parenchymal fraction (BPF). We compare
the homozygotes for the non-risk allele (AA) to the combined
heterozygotes (AG) and homozygotes (GG) for the risk allele. The
minor allele (G) frequency is 0.14.
doi:10.1371/journal.pone.0014169.g001
Table 1. Genotype correlation with baseline outcomes at study enrollment.
BRAIN VOLUME COGNITION
BASELINE BPF SDMT
SNP Chr Risk Allele Beta SE P Beta SE P
PICALM rs3851179 11 C 20.0017 0.0022 0.44 1.96 0.98 0.047
CR1 rs6656401 1 A 20.0020 0.0026 0.44 20.90 1.20 0.46
CLU rs11136000 8 C 20.0011 0.0021 0.60 20.09 0.90 0.92
PCK1 rs8192708 20 G 20.0087 0.0031 0.0047 21.23 1.35 0.36
ZNF224 rs3746319 19 A 20.0008 0.0028 0.77 2.16 1.19 0.07
Abbreviation: SNP, single nucleotide polymorphism; Chr, chromosome number; BPF, brain parechymal fraction; SDMT, symbol digit modalities test; PICALM,
phosphatidylinositol-binding clathrin assembly protein; CR1, complement component 3b/4b receptor 1; CLU, clusterin or apolipoprotein J; PCK1, phosphoenolpyruvate
carboxykinase 1; ZNF224, zinc finger protein.
doi:10.1371/journal.pone.0014169.t001
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AD-associated risk alleles at the five tested loci (range 0–10). When
correlating GRS with our primary outcomes, we did not observe
any statistically significant association with either brain volume or
cognition at baseline (Figure 2).
Causal Pathway Analysis
BPF is a measure of the neurodegenerative process, whereas
T2LV provides a coarse estimate for the cumulative burden of
inflammatory events in MS patients. Given current evidence
suggesting that genetic susceptibility for MS and early events are
largely related to immunologic dysfunction [21], we tested a model
in which the effect of the PCK1 allele, which is associated with both
smaller BPF and greater T2LV burden, might follow a causal
pathway such that inflammation triggers neurodegeneration.
Specifically, we examined whether the effect of the rs8192708
G
allele on T2LV mediates its effect on BPF by incorporating T2LV
as a covariate in the model assessing BPF. With the T2LV
covariate, the magnitude of the effect of rs8192708
G on BPF is
reduced by 34% (beta=20.005760.003, P=0.048) but the effect
is still present. Thus, the effect of the PCK1 locus on BPF may be
mediated in part by its effect on the extent of inflammatory disease
as estimated by T2LV, but the residual association in the presence
of the T2LV covariate suggests the existence of other mechanisms
responsible for the effect of the PCK1 locus on BPF.
Discussion
In this study, we used a candidate gene approach to explore
whether certain non-APOE genetic variants associated with AD
susceptibility influence neurodegeneration in MS as assessed by
measures of whole brain volume and cognition. Our principal
finding is that among the 722 MS subjects with MRI data, those
bearing the PCK1 allele associated with AD susceptibility may have
greater or accelerated brain atrophy. Specifically, an allele in the
PCK1 locus (rs8192708
G) exhibits correlation with a smaller
average BPF in our cohort of MS patients whose mean age at the
time of imaging is at least 25 years younger than the mean age in
late onset AD (75 years) [29]. This observation is intriguing and
suggests that elements of the neurodegenerative process in MS and
AD may be shared. Although the inciting events and certain key
pathologic findings are clearly different between MS and AD,
neuronal responses to perturbation in CNS parenchymal homeo-
stasis may well be similar.
Given our sample size, we have some statistical power to
discover modest effects such as the one we report in the PCK1
locus but do not have sufficient power to exclude the involvement
of the other four loci in MS-related neurodegeneration. Using the
approach of GRS to aggregate the effects of candidate loci, our
dataset does not exhibit evidence for modest effects in PICALM,
CR1, CLU or ZNF224. Additional fine mapping will be required to
determine whether rs8192708 is in fact the causal variant and
whether PCK1 is the causal gene for the observed association with
brain atrophy in MS. We did not have access to another MS
cohort of equivalent or greater sample size with MRI data to
independently validate our observation, but such an effort is
necessary in the future. Nonetheless, we provide evidence for
technical validation of the association between PCK1 and BPF by
reproducing the result when analyzing the BPF measure from the
last visit in the subset of subjects with more than one MRI scan.
PCK1 encodes phosphoenolpyruvate carboxykinase 1 (PEPCK),
a key enzyme in gluconeogenesis, responsible for converting
oxaloacetate to phosphoenolpyruvate. PEPCK has a wide tissue
expression pattern, including in the brain [30]. The AD risk-
associated allele in PCK1 (rs8192708
G) causes a missense mutation
(A to G) in the coding region, resulting in an isoleucine to valine
substitution at residue 267 (I267V). The crystal structure and the
kinetic properties of the rs8192708
G variant (V267) in human
cytosolic PEPCK are available [31,32], but in vitro data on the
isoleucine variant (I267) in human cytosolic PEPCK has not been
described. Comparison of the structural data on the rs8192708
G
variant (V267) and I267 from the highly homologous rat cytosolic
isozyme [33] (with 90% identity) illustrates the contribution of
residue 267 to the formation of a hydrophobic pocket adjacent to
the active site of the enzyme (Figure 3). Differences in the van der
Waals surface for isoleucine and valine demonstrates that
replacement of I267 by V267 creates a void in this pocket.
However, the structural data suggest that the protein fold
accommodates this void and that the I267V substitution does
not lead to perturbation of the local structure. Furthermore,
existing in vitro protein activity data on rat [34,35] and human [32]
PEPCK variants suggest that the I267V substitution does not have
significant functional consequences in in vitro systems. It remains a
possibility that the I267V substitution affects the stability and
folding properties of PEPCK because of the reduced packing
interaction (illustrated in Figure 3). Further in vitro investigations
of the I267V substitution within a single isozyme are necessary to
determine its structural and functional consequences.
Other variants in the PCK1 locus have shown modest evidence
of association with Type II Diabetes Mellitus (T2DM) [36,37].
Figure 2. Genetic risk score and baseline outcome. Genetic risk
score (GRS) for AD is calculated based on the number of AD-associated
risk alleles at the five tested loci borne by each subject. GRS is not
correlated with either (A) baseline brain parenchymal fraction (BPF,
n=722, P=0.096) or (B) baseline cognition (SDMT, n=318, P=0.20).
doi:10.1371/journal.pone.0014169.g002
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brain atrophy [38], and contributes to both vascular dementia and
Alzheimer’s disease [29]. We do not have T2DM as a systematic
outcome in our MS subjects, but an intriguing question is whether
the association of PCK1 with greater T2LV may represent: (a)
microvascular disease of the CNS parenchyma manifesting as
white matter hyperintensities; (b) an increased burden of
inflammatory disease activity; or (c) both. Regardless of the
mechanism by which PCK1 affects T2LV, this effect appears to
partially mediate the effect of PCK1 on brain atrophy, but much of
the effect appears to be mediated by other mechanisms.
Interestingly, this possible connection with an inflammatory effect
is further elaborated in that the effect of the PCK1 locus appears to
be driven by those subjects (n=463) who are positive for HLA
B*4402, an MHC class I allele previously associated with larger
BPF and lower T2LV in MS subjects [7]. Further investigation will
be needed to validate the interaction between PCK1 and HLA
B*4402. Other MHC alleles, such as HLA DRB1*1501, are also
associated with these outcomes [8,9]. However, we have not
reproduced the HLA DRB1*1501 association in our subjects and
therefore did not pursue additional stratified analyses.
Our study does not address how the PCK1 risk allele affect brain
volume in healthy control subjects of the same age group since we
do not have access to such a large cohort of subjects with genotype
and MRI or cognitive measures. Evaluating the effect of the PCK1
risk allele on the brain volume in healthy control subjects is an
important question for future investigation.
Since we have longitudinal MRI data on 641 subjects, we also
performed secondary analyses correlating the PCK1 locus with the
rate of change in BPF but did not find a significant association
(P=0.70). This is not surprising as the effect of PCK1 on cross-
sectional BPF and the average duration of follow-up (43.8 months)
are both modest. The change in BPF annually or over the study
period is too small when compared to the expected fluctuation in
MRI measurement from test to test. Thus, our statistical power is
limited in addressing this question, and we cannot yet distinguish
whether the effect of the PCK1 locus is one of accelerated brain
atrophy in the context of MS or whether PCK1 affects the maximal
BPF attained in the course of brain development.
Similarly, we are limited in our analysis of cognitive function
both because: (a) only a subset of subjects have cognitive outcome
(n=318, 44% of the cohort), and (b) although SDMT has become
increasingly adopted as a measure of cognition in MS patients, it
does not evaluate all cognitive domains and might thus
underestimate the extent of cognitive dysfunction. Therefore, we
cannot exclude the possibility that PCK1 may influence cognitive
manifestations of brain atrophy in MS.
In conclusion, our study suggests the existence of a shared
process of neurodegeneration or response to neurodegeneration
between MS and AD. Further work is needed to validate our
findings and explore the impact of this PCK1 variant on the
structural alterations in the PEPCK protein.
Supporting Information
Appendix S1 Supplemental Methods. Detailed Radiological
Analysis.
Found at: doi:10.1371/journal.pone.0014169.s001 (0.03 MB
DOC)
Table S1 Demographics of the study population.
Found at: doi:10.1371/journal.pone.0014169.s002 (0.06 MB
DOCX)
Table S2 Genotype distribution of candidate genes within the
cohort.
Found at: doi:10.1371/journal.pone.0014169.s003 (0.05 MB
DOC)
Figure S1 Effect of PCK1 (rs8192708
G) on the baseline BPF
using the additive model. The additive model demonstrates the
effect of PCK1 (rs8192708
G) on the baseline brain volume as
measured by BPF. We compare the homozygotes for the non-risk
allele (AA), heterozygotes (AG), and homozygotes (GG) for the risk
allele. The minor allele (G) frequency is 0.14.
Found at: doi:10.1371/journal.pone.0014169.s004 (9.12 MB TIF)
Acknowledgments
We thank participants in the CLIMB study and the staff at the Partners MS
Center and Broad Institute.
Author Contributions
Conceived and designed the experiments: ZX PLDJ. Performed the
experiments: BIG SJK TC HLW CG. Analyzed the data: ZX LBC ML
JMS DT TH. Contributed reagents/materials/analysis tools: TH. Wrote
the paper: ZX PLDJ. Critical revision of the manuscript: PLDJ LBC BIG
ML JMS.
References
1. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, et al. (1996)
Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain
119(Pt 6): 2009–2019.
2. Amato MP, Zipoli V, Portaccio E (2006) Multiple sclerosis-related cognitive changes:
a review of cross-sectional and longitudin a ls t u d i e s .JN e u r o lS c i2 4 5 :4 1 – 4 6 .
3. Zipoli V, Goretti B, Hakiki B, Siracusa G, Sorbi S, et al. (2010) Cognitive
impairment predicts conversion to multiple sclerosis in clinically isolated
syndromes. Mult Scler 16: 62–67.
4. Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis.
Lancet Neurol 7: 1139–1151.
Figure 3. Structural models of cytosolic PEPCK. Based on
previously published structural models of (A) rat cytosolic PEPCK
(isoleucine 267) (PDBID 3DT7 [33]) and (B) human cytosolic PEPCK
variant rs8192708
G (valine 267) (PDBID 1KHB [31]), the hydrophobic
pocket to which the residue at position 267 belongs is rendered as a
semi-transparent molecular surface colored by atom type (carbon,
green; oxygen, red; nitrogen, blue; sulfur, yellow). The van der Waals
surface for isoleucine (A) and valine (B) is rendered as a dotted yellow
surface. The metal ions are rendered as pink spheres, the catalytic and
metal binding residues are rendered as thin cylinders colored by atom
type and the substrates oxaloacetate (OAA) and guanosine triphos-
phate (GTP) are rendered as thick sticks, colored by atom type and
labeled.
doi:10.1371/journal.pone.0014169.g003
PCK1 and Brain Volume in MS
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e141695. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, et al. (2009) Cortical
lesions and atrophy associated with cognitive impairment in relapsing-remitting
multiple sclerosis. Arch Neurol 66: 1144–1150.
6. Martola J, Bergstrom J, Fredrikson S, Stawiarz L, Hillert J, et al. (2010) A
longitudinal observational study of brain atrophy rate reflecting four decades of
multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements
from MRI images. Neuroradiology 52: 109–117.
7. Healy BC, Liguori M, Tran D, Chitnis T, Glanz BI, et al. (2010) HLA B*44:
Protective effects in MS susceptibility and MRI outcome measures. Neurology in
press.
8. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, et al.
(2009) Genotype-Phenotype correlations in multiple sclerosis: HLA genes
influence disease severity inferred by 1HMR spectroscopy and MRI measures.
Brain 132: 250–259.
9. Zivadinov R, Uxa L, Bratina A, Bosco A, Srinivasaraghavan B, et al. (2007) HLA-
DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603
alleles are associated with more severe disease outcome on MRI in patients with
multiple sclerosis. Int Rev Neurobiol 79: 521–535.
10. Shi J, Zhao CB, Vollmer TL, Tyry TM, Kuniyoshi SM (2008) APOE epsilon 4
allele is associated with cognitive impairment in patients with multiple sclerosis.
Neurology 70: 185–190.
11. van der Walt A, Stankovich J, Bahlo M, Taylor BV, van der Mei IA, et al. (2009)
Apolipoprotein genotype does not influence MS severity, cognition, or brain
atrophy. Neurology 73: 1018–1025.
12. Burwick RM, Ramsay PP, Haines JL, Hauser SL, Oksenberg JR, et al. (2006)
APOE epsilon variation in multiple sclerosis susceptibility and disease severity:
some answers. Neurology 66: 1373–1383.
13. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009)
Genome-wide association study identifies variants at CLU and PICALM
associated with Alzheimer’s disease. Nat Genet 41: 1088–1093.
14. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genome-
wide association study identifies variants at CLU and CR1 associated with
Alzheimer’s disease. Nat Genet 41: 1094–1099.
15. Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, et al. (2007) Evidence
for novel susceptibility genes for late-onset Alzheimer’s disease from a genome-
wide association study of putative functional variants. Hum Mol Genet 16:
865–873.
16. Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, et al. (2009) Genome-
wide association study implicates a chromosome 12 risk locus for late-onset
Alzheimer disease. Am J Hum Genet 84: 35–43.
17. Shulman JM, Chibnik LB, Aubin C, Schneider JA, Bennett DA, et al. (2010)
Intermediate phenotypes identify divergent pathways to Alzheimer’s disease.
PLoS One 5: e11244.
18. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001)
Recommended diagnostic criteria for multiple sclerosis: guidelines from the
International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:
121–127.
19. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005)
Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘‘McDonald
Criteria’’. Ann Neurol 58: 840–846.
20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
21. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, et al. (2009) Meta-
analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as
new multiple sclerosis susceptibility loci. Nat Genet 41: 776–782.
22. Gauthier SA, Mandel M, Guttmann CR, Glanz BI, Khoury SJ, et al. (2007)
Predicting short-term disability in multiple sclerosis. Neurology 68: 2059–2065.
23. Meier DS, Guttmann CR (2006) MRI time series modeling of MS lesion
development. Neuroimage 32: 531–537.
24. Liu L, Meier D, Polgar-Turcsanyi M, Karkocha P, Bakshi R, et al. (2005)
Multiple sclerosis medical image analysis and information management.
J Neuroimaging 15: 103S–117S.
25. Wei X, Warfield SK, Zou KH, Wu Y, Li X, et al. (2002) Quantitative analysis of
MRI signal abnormalities of brain white matter with high reproducibility and
accuracy. J Magn Reson Imaging 15: 203–209.
26. Glanz BI, Holland CM, Gauthier SA, Amunwa EL, Liptak Z, et al. (2007)
Cognitive dysfunction in patients with clinically isolated syndromes or newly
diagnosed multiple sclerosis. Mult Scler 13: 1004–1010.
27. Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE,
et al. (2010) Psychometrics and normative data for the Multiple Sclerosis
Functional Composite: replacing the PASAT with the Symbol Digit Modalities
Test. Mult Scler 16: 228–237.
28. Cooper GF (1997) A simple constraint-based algorithm for efficiently mining
observational databases for causal relationships. Data Mining Knowledge Disc 1:
203–224.
29. Fotuhi M, Hachinski V, Whitehouse PJ (2009) Changing perspectives regarding
late-life dementia. Nat Rev Neurol 5: 649–658.
30. Hanson RW (2009) Thematic minireview series: a perspective on the biology of
phosphoenolpyruvate carboxykinase 55 years after its discovery. J Biol Chem
284: 27021–27023.
31. Dunten P, Belunis C, Crowther R, Hollfelder K, Kammlott U, et al. (2002)
Crystal structure of human cytosolic phosphoenolpyruvate carboxykinase reveals
a new GTP-binding site. J Mol Biol 316: 257–264.
32. Case CL, Mukhopadhyay B (2007) Kinetic characterization of recombinant
human cytosolic phosphoenolpyruvate carboxykinase with and without a His10-
tag. Biochim Biophys Acta 1770: 1576–1584.
33. Sullivan SM, Holyoak T (2008) Enzymes with lid-gated active sites must operate
by an induced fit mechanism instead of conformational selection. Proc Natl
Acad Sci U S A 105: 13829–13834.
34. Colombo G, Carlson GM, Lardy HA (1978) Phosphoenolpyruvate carbox-
ykinase (guanosine triphosphate) from rat liver cytosol. Separation of
homogeneous forms of the enzyme with high and low activity by chromatog-
raphy on agarose-hexane-guanosine triphosphate. Biochemistry 17: 5321–5329.
35. Johnson TA, Holyoak T (2010) Increasing the conformational entropy of the
Omega-loop lid domain in PEPCK impairs catalysis and decreases catalytic
fidelity. Biochemistry.
36. Beale EG, Hammer RE, Antoine B, Forest C (2004) Disregulated glyceroneo-
genesis: PCK1 as a candidate diabetes and obesity gene. Trends Endocrinol
Metab 15: 129–135.
37. Beale EG, Harvey BJ, Forest C (2007) PCK1 and PCK2 as candidate diabetes
and obesity genes. Cell Biochem Biophys 48: 89–95.
38. Tiehuis AM, van der Graaf Y, Visseren FL, Vincken KL, Biessels GJ, et al.
(2008) Diabetes increases atrophy and vascular lesions on brain MRI in patients
with symptomatic arterial disease. Stroke 39: 1600–1603.
PCK1 and Brain Volume in MS
PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e14169